0001209191-22-056427.txt : 20221110
0001209191-22-056427.hdr.sgml : 20221110
20221110171323
ACCESSION NUMBER: 0001209191-22-056427
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221108
FILED AS OF DATE: 20221110
DATE AS OF CHANGE: 20221110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Sanjiv
CENTRAL INDEX KEY: 0001816210
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39385
FILM NUMBER: 221378536
MAIL ADDRESS:
STREET 1: C/O RELAY THERAPEUTICS, INC.
STREET 2: 399 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Relay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001812364
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-370-8837
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-08
0
0001812364
Relay Therapeutics, Inc.
RLAY
0001816210
Patel Sanjiv
C/O RELAY THERAPEUTICS, INC.
399 BINNEY STREET, 2ND FLOOR
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2022-11-08
4
M
0
14000
4.12
A
268554
D
Common Stock
2022-11-08
4
S
0
14000
20.18
D
254554
D
Common Stock
2022-11-10
4
M
0
18175
4.12
A
272729
D
Common Stock
2022-11-10
4
S
0
18175
20.00
D
254554
D
Common Stock
2022-11-10
4
M
0
9825
5.04
A
264379
D
Common Stock
2022-11-10
4
S
0
9825
20.00
D
254554
D
Common Stock
674548
I
By The Patel Family Irrevocable Trust of 2019
Common Stock
432801
I
By The SSP Irrevocable Trust of 2020
Stock Option (Right to Buy)
4.12
2022-11-08
4
M
0
14000
0.00
D
2028-03-22
Common Stock
14000
18175
D
Stock Option (Right to Buy)
4.12
2022-11-10
4
M
0
18175
0.00
D
2028-03-22
Common Stock
18175
0
D
Stock Option (Right to Buy)
5.04
2022-11-10
4
M
0
9825
0.00
D
2029-04-22
Common Stock
9825
694779
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022.
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date.
The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date.
/s/ Brian Adams, as Attorney-in-Fact
2022-11-10